A Systematic Follow-Up of Mycobacterium tuberculosis Drug-Resistance and Associated Genotypic Lineages in the French Departments of the Americas over a Seventeen-Year Period

Table 4

Clusters (𝑛=21) of new cases containing at least 2 drug-resistant strains and corresponding drug-resistance profiles.

Cluster designation^a	SIT designation	Number of isolates^b	Number and proportion (%) of drug-resistant isolates^c	Drug-resistance profile^d	Year	Origin^d	MIT designation	VNTR defined subclusters^e
A	53	132	20 (15.2%)	S	1997	GLP		(A2)
				S	1999	GUF	8
				S	2004	GUF	33
				S	2004	GLP	802
				S	2011	GLP	1131
				I	1999	GLP	13
				I	1999	GUF		(A3)
				I	1999	GUF
				I	2000	GUF
				I	2001	GUF
				I	2001	GUF
				I	2002	MTQ
				I	2002	MTQ
				I	2003	GUF
				I	2004	GUF	382	A1
				I	2008	GUF	382
				I	2008	GUF	1459
				S, I	2002	GUF		(A4)
				S, I	1996	GLP
				S, I, R	2005	MTQ	32
B	50	110	5 (4.5%)	S	2003	GUF
				S	2004	GUF	42	B1
				I	2003	GLP	42
				R	2008	GLP	42
				S, I	2003	GLP	184
C	42	60	2 (3.3%)	S, I, R, E	2003	GUF
				I	2005	GLP	25
D	2	42	7 (16.7%)	I	1996	GUF		(D2)
				I	2010	GLP	350
				I, R	1996	GUF		(D3)
				I, R	1997	GUF
				S, I	1998	MTQ
				S, I	2005	GUF	810	D1
				S, I	2006	GUF	810
E	17	34	2 (5.9%)	I, R, E	1999	GLP	1542
				R	2011	GUF	26
F	14	31	6 (19.4%)	S	1997	GLP		(F1)
				S	1997	GLP
				S	1997	GLP
				S	2010	GLP	24
				I	1998	GLP	28	(F2)
				I	2000	MTQ
G	20	29	14 (48.3%)	S	2009	GUF	25
				I	2001	GUF
				I	2001	GUF
				I	2004	GLP	307	G1
				I	2004	GUF	307
				I	2004	GUF	307
				I	2006	GUF	307
				I	2006	GUF	307
				I	2009	GUF	307
				I	1999	GLP	1048	G2
				S, I, R	2000	GUF	1048
				S, I, R	2001	GUF	1048
				I, R	2001	GUF		(G3)
				I, R	2002	GUF
H	93	27	4 (14.8%)	S, I	1997	GUF
				I, R	1999	GLP	25	H1
				I, R	2006	GUF	25
				R	2004	GLP	25
I	64	24	6 (25.0%)	S, P	1997	GUF		(I1)
				S, P	1999	GUF
				S, P	2001	GUF
				S, P	2001	GUF
				S, P	2002	GUF
				S	2006	GUF	328
J	1	17	3 (17.6%)	S, I	2002	GUF		(J1)
				S, I	2002	GUF
				S, I	2003	GUF
K	46	16	8 (50.0%)	S	1999	MTQ		(K1)
				S	1999	MTQ
				S	1999	MTQ
				S	1999	MTQ
				S	1999	MTQ
				S	1999	MTQ
				S	1999	MTQ
				S	1999	MTQ
L	45	16	5 (31.3%)	S	2004	MTQ	23	L1
				S	2009	MTQ	23
				S	2008	GLP	34	L2
				S	2011	GLP	34
				S	2008	MTQ	Orphan
M	1340	15	2 (13.3%)	I, R	2000	GUF
				R	2004	GUF	798
N	92	8	6 (75.0%)	I	1998	GUF	3	N1
				I	1998	GUF	3
				I	1998	GUF	3
				I	2005	GUF	3
				I	2009	GUF	3
				I	2001	GUF
O	129	8	4 (50.0%)	P	1996	GUF	1089	O1
				S	2008	GUF	1089
				S	2011	GUF	1089
				S	2011	GUF	1089
P	5	8	3 (37.5%)	S, I, R, E	2005	GLP	15	P1
				S, I, R, E	2006	GUF	15
				I, E	2008	GUF	Orphan
Q	334	5	2 (40.0%)	S, I, R	2002	GUF
				I	2003	GUF
R	482	4	4 (100%)	P	1996	GLP		(R1)
				P	1998	GLP
				P	2004	GUF	49
				I, P	2010	GUF	281
S	75	4	2 (50.0%)	I	2003	GLP
				I, R	2004	GUF	42
T	385	3	2 (50.0%)	I	1999	GUF		(T1)
				I	2003	MTQ
U	2884	2	2 (100%)	S	1999	MTQ		(U1)
				S	2006	MTQ	25

^a𝑛=21/115 clusters (labeled A-U) identified based on spoligotyping results of new cases included at least 2 resistant isolates.
bIn total, 595 isolates are grouped in the 21 clusters defined in^a.
^c𝑛=109/595 clustered cases are caused by resistant strains.
dI: isoniazid, R: rifampicin, S: streptomycin, E: ethambutol, P: pyrazinamide dGLP: Guadeloupe, MTQ: Martinique, GUF: French Guiana.
eSubclusters defined by spoligotypes and MIRU-VNTR profiles (SIT and MIT); subclusters in parentheses were defined based on resistance profiles only (incomplete or missing MIRU data), while those in bold were defined based on both molecular typing and drug-resistance profiles.